# Tirzepatide: Dual GIP/GLP-1 Receptor Agonist — Research Record | Medicinal Tirzepatide > Tirzepatide is a 39-amino-acid synthetic peptide that acts as a dual GIP and GLP-1 receptor agonist. Nine phase-3 programs. Endpoints, mechanism, and pharmacokinetics indexed from the literature. A technical index of the published SURPASS and SURMOUNT research record. Mechanism, endpoints, pharmacokinetics, and safety data — numbered, cited, annotated. ## Tirzepatide as a Synthetic Peptide: Structural Overview Tirzepatide (LY3298176). Molecular formula: 39-amino-acid synthetic linear peptide. Molecular weight: 4813.5 Da. Structural basis: derived from the native GIP (glucose-dependent insulinotropic polypeptide) sequence, with modifications including a C20 fatty diacid moiety attached via a linker to Lys26 — the same albumin-binding strategy used to extend plasma half-life in other acylated incretin-class peptides [1]. The fatty diacid modification is what gives tirzepatide its approximately 5-day terminal half-life, enabling once-weekly subcutaneous administration across all nine phase-3 clinical programs [18]. At the receptor level, tirzepatide is classified as an imbalanced and biased dual GIP/GLP-1 receptor agonist. It binds the GIP receptor (GIPR) with potency equivalent to native GIP. At the GLP-1 receptor (GLP-1R) it is approximately five-fold weaker than native GLP-1 — but crucially, it shows biased signaling at GLP-1R, favoring cyclic AMP (cAMP) generation over beta-arrestin recruitment [1]. Reduced beta-arrestin recruitment slows receptor internalization, which may sustain receptor-level signaling at the GLP-1R. This receptor pharmacology profile distinguishes tirzepatide from selective GLP-1 receptor agonists in the incretin class. Tirzepatide is not a natural peptide. It is a purpose-engineered synthetic molecule. The structural design choices — GIP backbone, C20 fatty diacid, biased GLP-1R agonism — are the molecular engineering decisions that produced the clinical trial outcomes documented across the SURPASS and SURMOUNT programs [4, 5]. ## What is tirzepatide? A 39-amino-acid synthetic peptide that simultaneously activates the GIP and GLP-1 receptor systems. Studied in adults with type 2 diabetes (SURPASS program, 5 trials), adults with obesity (SURMOUNT program, 4 trials), adults with obstructive sleep apnea and obesity (SURMOUNT-OSA), and adults with type 2 diabetes at elevated cardiovascular risk (SURPASS-CVOT). FDA-approved for type 2 diabetes (May 2022), chronic weight management (November 2023), and obstructive sleep apnea (December 2024) [16]. ## Tirzepatide and weight regulation: dual incretin mechanism Dual GIP/GLP-1 agonism produces weight reduction through at least four documented pathways: hypothalamic appetite suppression via incretin receptor signaling; gastric emptying delay, which extends the satiety window; weight-loss-independent improvements in peripheral insulin sensitivity; and direct GIP receptor-mediated effects on adipocyte nutrient metabolism [21]. In SURMOUNT-1 (n=2,539, adults with obesity without type 2 diabetes, 72 weeks), tirzepatide at 5 mg, 10 mg, and 15 mg produced mean body weight reductions of 16.0%, 21.4%, and 22.5% respectively, versus 2.4% for placebo [6]. The 22.5% mean reduction at the 15 mg dose was the largest mean weight loss reported in a placebo-controlled trial for any approved agent at the time of publication. A 2024 study in Cell Metabolism confirmed functional GIPR expression in both human and mouse adipocytes, demonstrating that tirzepatide activates GIP signaling in adipose tissue to enhance lipolysis and nutrient efflux [21]. This GIP receptor pathway is absent from selective GLP-1 receptor agonists — and is the mechanistic basis for the observed weight differential in [tirzepatide vs semaglutide](/research#vs-semaglutide) head-to-head research. For detailed [SURMOUNT weight loss results](/research#weight-loss) including dose-specific percentages, body composition data, and the SURMOUNT-5 head-to-head comparison, see the research page. ## Is tirzepatide a GLP-1 receptor agonist? Tirzepatide activates both the GLP-1 receptor and the GIP receptor simultaneously. It is classified as a dual incretin receptor agonist — not a selective GLP-1 receptor agonist. This dual-receptor pharmacology is its primary structural and pharmacological differentiator from the preceding incretin class. At the GLP-1R, tirzepatide exhibits biased agonism: preferential activation of cAMP signaling over beta-arrestin recruitment [1]. At the GIPR, it is equivalent in potency to native GIP. Neither of these receptor-level properties is replicated by selective GLP-1 receptor agonists, which bind only the GLP-1R and do not engage the GIP receptor pathway. This classification matters for interpreting the trial data. The outcomes in SURPASS-2 (superior glycemic control versus semaglutide 1 mg) [3] and SURMOUNT-5 (superior weight reduction versus semaglutide 2.4 mg) [10] are plausibly explained by the additive GIP receptor engagement that selective GLP-1 agonists do not provide. ## Compounded tirzepatide: research context Compounded tirzepatide refers to tirzepatide active pharmaceutical ingredient formulated by licensed compounding pharmacies. The base molecule is structurally identical to the tirzepatide described in the SURPASS and SURMOUNT trial literature. Compounded formulations are not FDA-approved for any indication and are not evaluated or referenced in the phase-3 trial literature. For [storage and reconstitution protocols](/dosage#storage) relevant to tirzepatide research samples, see the dosage page. The C20 fatty diacid modification that enables albumin binding in the approved formulation also introduces acylated peptide degradation pathways — aggregation, deamidation, oxidation — that make storage conditions relevant to stability [18]. --- A numbered schematic reading of the tirzepatide trial record — SURPASS and SURMOUNT endpoints indexed, mechanism annotated, no clinical position held.